AR Negative serves as an inclusion eligibility criterion in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials that contain AR Negative as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open).
Trials with AR Negative in the inclusion eligibility criteria most commonly target breast carcinoma and prostate adenocarcinoma .
Cisplatin, mln1117, abiraterone, enzalutamide, and erdafitinib are the most frequent therapies in trials with AR Negative as an inclusion criteria .
Significance of AR Negative in Diseases
Breast Carcinoma +
AR is mutated in 1.42% of breast carcinoma patients .
AR Negative is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain AR Negative and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) .
Prostate Adenocarcinoma +
AR is mutated in 13.77% of prostate adenocarcinoma patients .
AR Negative is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AR Negative and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.